NCT03242460View on ClinicalTrials.gov

The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 12, 2015

Primary Completion Date

April 24, 2019

Study Completion Date

May 2, 2019

Conditions
Relapsed and/or refractorY Multiple Myeloma
Interventions
DRUG

Pomalidomide 4 MG

Pomalidomide 4mg Days 1-21

DRUG

Dexamethasone 20mg

Dexamethasone 20mg Days 1, 8, 15, 22

DRUG

Cyclophosphamide 400mg

Cyclophosphamide 400mg Days 1, 8, 15

Trial Locations (1)

Unknown

Catholic university of korea, Seoul ST. Mary's Hospital., Seoul

All Listed Sponsors
lead

Kosin University Gospel Hospital

OTHER

NCT03242460 - The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) | Biotech Hunter | Biotech Hunter